Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofrontera AG's gross profit for the
three
months ended in Mar. 2026 was €3.01 Mil. Biofrontera AG's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €11.23 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Biofrontera AG's gross profit for the
three
months ended in Mar. 2026 was €3.01 Mil. Biofrontera AG's Revenue for the
three
months ended in Mar. 2026 was €3.71 Mil. Therefore, Biofrontera AG's Gross Margin % for the quarter that ended in Mar. 2026 was 80.91%.
Biofrontera AG had a gross margin of 80.91% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Biofrontera AG was 88.35%. The lowest was 73.05%. And the median was 82.87%.
Warning Sign:
Biofrontera AG gross margin has been in long-term decline. The average rate of decline per year is -1.3%.
Biofrontera AG (LTS:0DOL) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biofrontera AG had a gross margin of 80.91% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Biofrontera AG Gross Profit Related Terms
Biofrontera AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DOL vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.23 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biofrontera AG (LTS:0DOL) has a Gross Profit of €11.23 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's Gross Profit too high?
Biofrontera AG's current Gross Profit is €11.23 Mil. Overall, Biofrontera AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Gross Profit compare to ZTS and UTHR?
Biofrontera AG's Gross Profit of €11.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Gross Profit is €11.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current Gross Profit of €11.23 Mil. The stock's GF Value™ is €2.27, compared to a current price of €2.55 — trading 12.3% above its estimated fair value. The current Gross Profit is €11.23 Mil. Biofrontera AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Gross Profit is €11.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued.
The current stock price of €2.55 is trading 12.3% above its estimated GF Value™ of €2.27.
Key valuation signals for LTS:0DOL:
Gross Profit: €11.23 Mil
GF Value™: €2.27 vs. price of €2.55 (12.3% above fair value)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
61GF Score
Get the complete analysis for LTS:0DOL
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
